Reduction of immune inhibitory myeloid derived suppressor cells by low dose sunitinib combined with a cancer vaccine to provide therapeutic benefit to tumor-bearing mice.
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Tags: cancer, imatinib-resistant gastrointestinal stromal tumors (GIST), pancreatic neuroendocrine tumors (pNET), receptor tyrosine kinase (RTK) inhibitor, renal cell carcinoma (RCC), Sutent®
BASi Method Number SAP.1124
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
